Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, UK.
Int J Drug Policy. 2011 Jul;22(4):274-7. doi: 10.1016/j.drugpo.2011.02.006. Epub 2011 Apr 8.
Spice is the iconic brand name of a smokeable herbal mixture containing synthetic cannabinoid receptor agonists. It has been available on the Internet/in head shops in Europe since at least 2006. The synthetic cannabinoid receptor agonist constituents of Spice were classified in the UK as Class B agents in December 2009. This study assessed the impact of this legislation on the synthetic cannabinoid receptor agonists present in Spice products and whether new synthetic cannabinoid receptor agonists outside of the legislation are now available.
Spice products were bought, prior to and after the change in the UK legislation, from a range of Internet legal high websites selling to UK consumers. Products were analysed using liquid chromatography high-resolution tandem mass spectrometry (LCMSMS). Identification of the synthetic cannabinoid receptor agonist(s) detected was made by comparison to existing databases or by 'in silico' methods.
Sixteen products were purchased prior to the UK control of synthetic cannabinoid receptor agonists; all contained at least one synthetic cannabinoid receptor agonist. 20 products were purchased after the UK control; no active compounds were detected in 3 (15%). The remaining 17 (85%) all contained at least one classified synthetic cannabinoid receptor agonist. Additionally, 2 synthetic cannabinoid receptor agonists not covered under current UK generic legislation (AM-694 and the 'novel Belarus compound') were detected.
Despite the UK 'Spice' classification, classified synthetic cannabinoid receptor agonists continue to be supplied over the Internet to UK users. Furthermore, new synthetic cannabinoid receptor agonists not covered by the legislation are appearing. Consideration needs to be given to reviewing the UK legislation so that suppliers cannot circumvent it by supplying legal alternatives to the classified synthetic cannabinoid receptor agonists.
香料是一种可吸食的草药混合物的标志性品牌名称，其中含有合成大麻素受体激动剂。自 2006 年以来，它一直在欧洲的互联网/专卖店中销售。2009 年 12 月，英国将合成大麻素受体激动剂成分列为 B 类药物。本研究评估了这一立法对香料产品中存在的合成大麻素受体激动剂的影响，以及现在是否有新的不在立法范围内的合成大麻素受体激动剂。
在英国立法发生变化之前和之后，从一系列向英国消费者销售的互联网合法高网站购买香料产品。使用液相色谱-高分辨率串联质谱法（LCMSMS）对产品进行分析。通过与现有数据库进行比较或通过“计算”方法确定检测到的合成大麻素受体激动剂的身份。
在英国控制合成大麻素受体激动剂之前，购买了 16 种产品；所有产品均含有至少一种合成大麻素受体激动剂。在英国控制之后，购买了 20 种产品；3 种（15%）产品中未检测到活性化合物。其余 17 种（85%）产品均含有至少一种被分类的合成大麻素受体激动剂。此外，还检测到 2 种不受英国现行通用立法管制的合成大麻素受体激动剂（AM-694 和“新型白俄罗斯化合物”）。
尽管英国对“香料”进行了分类，但仍有分类的合成大麻素受体激动剂通过互联网供应给英国用户。此外，不受立法管制的新的合成大麻素受体激动剂也在出现。需要考虑审查英国立法，以便供应商不能通过供应被分类的合成大麻素受体激动剂的合法替代品来规避该立法。
